Research And Markets Research And Markets
0 CHECKOUT

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts

  • ID: 3292819
  • April 2016
  • Region: Global
  • 188 Pages
  • CurrentPartnering
1 of 4

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking

2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments7
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals

3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers

4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory

5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Vaccine deals by company A-Z

Appendix 2 - Cancer Vaccine deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Cancer Vaccine deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions

About

Recent report titles

Table of figures

Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity- 2010 to 2016
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Note: Product cover images may vary from those shown
3 of 4

Global Cancer Vaccine Partnering 2010-2016 report provides the reader with the following key benefits:

- In-depth understanding of Cancer Vaccine deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
- Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
- Identify most active Cancer Vaccine dealmakers since 2010
- Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db